All articles by GlobalData Healthcare

  1. Non-profit licensing deal values climb in 2016

    In 2016, there was a surge in deal values between the biopharmaceutical industry and non-profit organizations. While the number of…
    Read More…

    22 Mar
  2. Personalised medicine is the future of cancer treatment

    Cancer therapy as we know it is evolving. With many patients not responding or reacting badly to generalised treatment, it…
    Read More…

    21 Mar
  3. Move Over, Zika and Ebola – the next global epidemic could be metabolic

    These are challenging times in the public health front, as a new disease epidemic, each with its own challenges to…
    Read More…

    21 Mar
  4. Non-alcoholic steatohepatitis cases expected to nearly double over next decade

    Non-alcoholic steatohepatitis (NASH) is a common, often clinically silent liver disease characterized by the presence of fat in the liver,…
    Read More…

    21 Mar
  5. Pharmacoeconomics: a crushing reality in today’s industry

    Times are tough in the healthcare industry today. The increase in prevalence of chronic diseases, an aging population, rising drug…
    Read More…

    17 Mar
  6. Antibiotic stewardship: can we learn from England’s C. difficile success?

    Driven by the emergence of new hypervirulent strains, Clostridium difficile infections (CDIs) have been on the rise since the early…
    Read More…

    14 Mar
  7. Ohr Pharmaceuticals is determined to show efficacy for Squalamine despite setbacks

    On 21 February, Ohr Pharmaceuticals announced the closure of its small lab in San Diego, California, US, which focused on…
    Read More…

    8 Mar
  8. WHO appeal for new antibiotics lacks necessary incentives

    In a recent announcement, the World Health Organization (WHO) highlighted the need for novel antibiotics to combat a variety of…
    Read More…

    6 Mar
  9. Pfizer seeking a timely re-launch of Mylotarg in AML amid increasing competition

    In January 2017, Pfizer submitted a new application to the FDA for its controversial leukemia drug Mylotarg (gemtuzumab ozogamicin), which…
    Read More…

    3 Mar
  10. NSCLC incidence continues to increase in urban China

    Lung cancer has become the most common cancer in China. GlobalData’s epidemiology forecast for non-small cell lung cancer (NSCLC), which…
    Read More…

    3 Mar
Close
Close
Close

Go Top